Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
ACHFF
Primary Symbol:
V.ARCH
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok...
). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Apr 07, 2023 10:06am
RE:RE:RE:RE:RE:HUGE NEWS : $4 MILLION IN FUNDING FROM NRC
The premise of both of your replies are repetitively hostile as they always have been in the past. Whether you're the intended person of my posts or not you like Psychological Projection. Also
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Comment by
Riverfolk
on Apr 07, 2023 9:33am
RE:RE:RE:RE:HUGE NEWS : $4 MILLION IN FUNDING FROM NRC
Thank you for speaking honestly and with hostility this morning as it lets the readers understand your motives. I will continue to support the facts and provide links to back them up. As the Prime
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Apr 07, 2023 8:55am
RE:RE:RE:HUGE NEWS : $4 MILLION IN FUNDING FROM NRC
There was a 100% chance you would bite the hook this morning with a reply. The early bird always catches the worm. If one follows your cut and paste posts you always deem to be "Due Diligence
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Apr 07, 2023 6:43am
RE:HUGE NEWS : $4 MILLION IN FUNDING FROM NRC
The timeline for Arch's use of 4M in government funding is one that throws everything at the wall everywhere all at once. The probability of Arch ever getting to an FDA approval remains a very
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Mar 23, 2023 9:10am
HUGE NEWS : $4 MILLION IN FUNDING FROM NRC
TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company
...more
(20)
•••
Bertie20
X
View Profile
View Bullboard History
Post by
Bertie20
on Mar 23, 2023 7:40am
Positive news: funding
TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel
...more
(2)
•••
williepoker
X
View Profile
View Bullboard History
Comment by
williepoker
on Feb 24, 2023 3:24pm
RE:RE:Hello?
SINKING SHIP!
(5)
•••
TheBearInTheWoods
X
View Profile
View Bullboard History
Comment by
TheBearInTheWoods
on Feb 22, 2023 10:17pm
RE:Hello?
Buddy your stock pick in 2020 AGN is down from .56 to .02 and you want comment that Arch is down from $5 to 2.17 Glad you came out of your hole when the markets are down though, you crack me up.
...more
(2)
•••
williepoker
X
View Profile
View Bullboard History
Post by
williepoker
on Feb 22, 2023 12:56pm
Hello?
So? Where are the pumpers? Hello? Riverfolk? Shareprice speaks for itself!
(54)
•••
GoldenArm
X
View Profile
View Bullboard History
Comment by
GoldenArm
on Feb 08, 2023 3:31pm
RE:RE:CATCO Trial
Yeah but the vaccine causes adverse effects 1 in 1500 including myocarditis and Pericarditis are inflamations that the drug can treat. Since mRNA did not stop spread the odds of inflamation in people
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Comment by
Riverfolk
on Jan 30, 2023 10:47am
RE:CATCO Trial
The CATCO trial is sponsored by Sunnybrook Health Sciences Center and funded by the federal governement. The only involvement that Arch Biopartners had was providing the drug needed to dose the
...more
(6)
•••
Arbourmark
X
View Profile
View Bullboard History
Post by
Arbourmark
on Jan 30, 2023 7:43am
CATCO Trial
Where do we stand on the CATCO trial. This news was announced Feb 14,2022? When will we get an update on results of that trial? When will an independent peer review be published? https://stockhouse
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Jan 18, 2023 12:57pm
Potential 1st-Ever Drug Discovery to Treat Acute Kidney Inju
Raymond James Coverage Initiated: New MoA vs. Organ Inflammation | Potential 1st-Ever Drug to Treat Acute Kidney Injury RECOMMENDATION We initiate coverage of ARCH with a C$3.50 target and Market
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 15, 2022 9:50am
New Press Release - Shares for Interest Debt Settlement; Grants Options
TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $201,459 in interest accrued up to September 30, 2022 on all five...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Drilling Approval Received for New Mexico Lithium Project
GameSquare Announces Formation of FaZe Media, Backed by $11M Investment
Xcyte Digital Corp. Releases "Xperience" Subscription Service